T-cell acute lymphoid leukemia resembling Burkitt leukemia cell morphology: A case report

Yue,Qingfang; Liu,Xinyue; Chen,Lei; Liu,Zhongping; Chen,Wanxin

doi:10.3892/ol.2014.2825

T-cell acute lymphoid leukemia resembling Burkitt leukemia cell morphology: A case report

Authors:
- Qingfang Yue
- Xinyue Liu
- Lei Chen
- Zhongping Liu
- Wanxin Chen
View Affiliations

Affiliations: Department of Hematology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: December 23, 2014 https://doi.org/10.3892/ol.2014.2825
Pages: 1236-1238

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Biphenotypic acute leukemia (BAL) is an uncommon type of cancer, which accounts for <5% of all adult ALs. Based upon a previously described scoring system, the European Group for the Immunological Classification of Leukemias (EGIL) proposed a set of diagnostic criteria for BAL. This scoring system is based upon the number and degree of specificity of several markers for myeloid or T/B‑lymphoid blasts. The present study describes a case of T‑cell acute lymphoblastic leukemia (T‑ALL) with Burkitt‑like cytology, which according to the French‑American‑British classification, corresponded to a diagnosis of Burkitt type L3 ALL. Flow cytometry analysis demonstrated that the blasts were positive for T‑lymphoid markers, cytoplasmic cluster of differentiation (CD)3, CD7 and CD56, and myeloid markers, CD13, CD33 and CD15. At first, a diagnosis of BAL was suggested by the EGIL score, however, according to the 2008 World Health Organization criteria, a case of T‑ALL with aberrant myeloid markers was established. The study also reviewed the literature and discussed the limitations of the EGIL scoring system in clinical decision making, to aid in the selection of an appropriate therapeutic regimen.

View Figures

View References

1	Paietta E: Proposals for the immunological classification of acute leukemias. Leukemia. 9:2147–2148. 1995.PubMed/NCBI
2	Buccheri V, Matutes E, Dyer MJ and Catovsky D: Lineage commitment in biphenotypic acute leukemia. Leukemia. 7:919–927. 1993.PubMed/NCBI
3	Swerdlow SH, Campo E, Harris NL, et al: Acute leukemias of ambiguous lineage. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC; Lyon: pp. 149–155. 2008
4	Matutes E, Morilla R, Farahat N, et al: Definition of acute biphenotypic leukemia. Haematologica. 82:64–66. 1997.PubMed/NCBI
5	Buccheri V, Matutes E, Dyer MJ and Catovsky D: Lineage commitment in biphenotypic acute leukemia. Leukemia. 7:919–927. 1993.PubMed/NCBI
6	Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
7	Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999.PubMed/NCBI
8	Weir EG, Ali Ansari-Lari M, Batista DA, et al: Acute bilineal leukemia: a rare disease with poor outcome. Leukemia. 21:2264–2270. 2007. View Article : Google Scholar : PubMed/NCBI
9	Rubnitz JE, Onciu M, Pounds S, et al: Acute mixed lineage leukemia in children: the experience of St Jude Children’s Research Hospital. Blood. 113:5083–5089. 2009. View Article : Google Scholar : PubMed/NCBI
10	Carbonell F, Swansbury J, Min T, et al: Cytogenetic findings in acute biphenotypic leukaemia. Leukemia. 10:1283–1287. 1996.PubMed/NCBI
11	Bene MC, Castoldi G, Knapp W, et al: Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 9:1783–1786. 1995.PubMed/NCBI
12	Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
13	Suggs JL, Cruse JM and Lewis RE: Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol. 83:471–473. 2007. View Article : Google Scholar : PubMed/NCBI
14	Coche D, Bergues B, Harrivel V and Guillaume N: Biphenotypic acute leukaemia with Burkitt-like cytology. Ann Biol Clin (Paris). 67:437–440. 2009.(In French).
15	Hecht JL and Aster KC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 18:3707–3721. 2000.PubMed/NCBI
16	Neri A, Barriga M, Knowles DM, et al: Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci USA. 85:2748–2752. 1988. View Article : Google Scholar : PubMed/NCBI
17	Gerbitz A, Mautner J, Geltinger C, Hörtnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A and Bornkamm GW: Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt’s lymphoma. Oncogene. 18:1745–1753. 1999. View Article : Google Scholar : PubMed/NCBI
18	Aribi A, Bueso-Ramos C, Estey E, et al: Biphenotypic acute leukaemia: a case series. Br J Haematol. 138:213–216. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zucchini A, Fattori PP, Lanza F, et al: Biphenotypic acute leukemia: a case report. J Biol Regul Homeost Agents. 18:387–391. 2004.